JP7671307B2 - Ｈ４アンタゴニスト化合物 - Google Patents

Ｈ４アンタゴニスト化合物 Download PDF

Info

Publication number
JP7671307B2
JP7671307B2 JP2022564280A JP2022564280A JP7671307B2 JP 7671307 B2 JP7671307 B2 JP 7671307B2 JP 2022564280 A JP2022564280 A JP 2022564280A JP 2022564280 A JP2022564280 A JP 2022564280A JP 7671307 B2 JP7671307 B2 JP 7671307B2
Authority
JP
Japan
Prior art keywords
acid
pyrazol
methyl
pyrimidin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022564280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522405A5 (https=
JP2023522405A (ja
Inventor
コングリーヴ，マイルズ・スチュアート
フィールドハウス，シャーロット
スウェイン，ナイジェル・アラン
ピックワース，マーク
ハンナ，ダンカン・ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70859977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7671307(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of JP2023522405A publication Critical patent/JP2023522405A/ja
Publication of JP2023522405A5 publication Critical patent/JP2023522405A5/ja
Application granted granted Critical
Publication of JP7671307B2 publication Critical patent/JP7671307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022564280A 2020-04-22 2021-04-22 Ｈ４アンタゴニスト化合物 Active JP7671307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005858.2 2020-04-22
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds
PCT/GB2021/050971 WO2021214469A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds

Publications (3)

Publication Number Publication Date
JP2023522405A JP2023522405A (ja) 2023-05-30
JP2023522405A5 JP2023522405A5 (https=) 2024-05-02
JP7671307B2 true JP7671307B2 (ja) 2025-05-01

Family

ID=70859977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564280A Active JP7671307B2 (ja) 2020-04-22 2021-04-22 Ｈ４アンタゴニスト化合物

Country Status (12)

Country Link
US (1) US20230167094A1 (https=)
EP (1) EP4139300A1 (https=)
JP (1) JP7671307B2 (https=)
KR (1) KR20230004512A (https=)
CN (1) CN115916770B (https=)
AU (1) AU2021260142A1 (https=)
BR (1) BR112022021395A2 (https=)
CA (1) CA3180853A1 (https=)
GB (1) GB202005858D0 (https=)
IL (1) IL297469A (https=)
MX (1) MX2022013340A (https=)
WO (1) WO2021214469A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
WO2008060766A2 (en) 2006-10-02 2008-05-22 Abbott Laboratories Histamine h4 receptor ligands for use in pain treatment
JP7532353B2 (ja) 2018-10-19 2024-08-13 ネクセラ・ファーマ・ユーケイ・リミテッド Ｈ４アンタゴニスト化合物としてのピラゾール誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
WO2008060766A2 (en) 2006-10-02 2008-05-22 Abbott Laboratories Histamine h4 receptor ligands for use in pain treatment
JP7532353B2 (ja) 2018-10-19 2024-08-13 ネクセラ・ファーマ・ユーケイ・リミテッド Ｈ４アンタゴニスト化合物としてのピラゾール誘導体

Also Published As

Publication number Publication date
CN115916770A (zh) 2023-04-04
MX2022013340A (es) 2023-02-22
JP2023522405A (ja) 2023-05-30
KR20230004512A (ko) 2023-01-06
AU2021260142A1 (en) 2022-11-17
BR112022021395A2 (pt) 2022-12-13
GB202005858D0 (en) 2020-06-03
WO2021214469A1 (en) 2021-10-28
EP4139300A1 (en) 2023-03-01
CN115916770B (zh) 2025-02-28
IL297469A (en) 2022-12-01
US20230167094A1 (en) 2023-06-01
CA3180853A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2020202000B2 (en) Bipyrazole derivatives as jak inhibitors
JP7532353B2 (ja) Ｈ４アンタゴニスト化合物としてのピラゾール誘導体
HK1245769A1 (en) Bipyrazole salt as jak inhibitor
EP2933248B1 (en) Novel renin inhibitor
WO2013026025A1 (en) Cyclohexyl azetidine derivatives as jak inhibitors
CA3066946A1 (en) Heteroaromatic compounds as vanin inhibitors
KR20160037996A (ko) 헤테로바이사이클로아릴 rorc2 억제제 및 이의 사용 방법
JP2010540424A (ja) チエノピリミジン化合物類および組成物
JP2010540422A (ja) チエノピリミジン化合物類
JP7671307B2 (ja) Ｈ４アンタゴニスト化合物
RU2837355C1 (ru) Соединения-антагонисты н4
JP7764479B2 (ja) Ｈ４アンタゴニスト化合物
RU2821516C2 (ru) Пиразольные производные в качестве соединений-антагонистов h4
WO2025076632A1 (en) Compounds and uses thereof
HK40103736B (en) Bipyrazole derivatives as jak inhibitors
HK1221466B (en) Bipyrazole derivatives as jak inhibitors
EA043636B1 (ru) АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157